MedTrace Logo

Gut Peptides and Bone Remodeling in Children With Neuromuscular Disorders

NCT07254988 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2026-04-16

No results posted yet for this study

Summary

Both GIP and GLP-2 reduce bone resorption (measured as CTX) in healthy adult individuals. In this study, we will investigate whether GIP and GLP-2 reduce CTX in children with spinal muscular atrophy, duchenne muscular dystrophy, or cerebral palsy.

Conditions

  • Cerebral Palsy (CP)
  • Spinal Muscular Atrophy (SMA)
  • Duchenne Muscular Dystrophy (DMD)

Interventions

OTHER

Meal test

Ingestion of an oral liquid meal (nutridrink), 3.3 mL/kg body weight.

OTHER

GIP + GLP-2

Subcutaneous GIP + GLP-2 injection (1 mL containing 100 microgram GIP + 1 mL containing 400 microgram GLP-2).

OTHER

Placebo

Subcutaneous saline injection (2 mL isotonic saline).

Sponsors & Collaborators

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Mette Marie Rosenkilde · University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
10 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-24
Primary Completion
2025-12-01
Completion
2025-12-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07254988 on ClinicalTrials.gov